Application of handgrip therapy based on TCM meridian theory in patients with exogenous fever

注册号:

Registration number:

ITMCTR2024000651

最近更新日期:

Date of Last Refreshed on:

2024-11-03

注册时间:

Date of Registration:

2024-11-03

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

基于中医经络理论的握药疗法在外感发热患者中的应用

Public title:

Application of handgrip therapy based on TCM meridian theory in patients with exogenous fever

注册题目简写:

握药疗法

English Acronym:

handgrip therapy

研究课题的正式科学名称:

基于中医经络理论探讨握药疗法对外感发热患者退热效果的研究

Scientific title:

Study on the theory of traditional Chinese medicine meridian theory to explore the research on the effects of antipyretic fever effect on external sensing therapy

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

曾桂珍

研究负责人:

邓秋迎

Applicant:

Zeng Guizhen

Study leader:

Deng Qiuying

申请注册联系人电话:

Applicant telephone:

+86 137 1934 6240

研究负责人电话:

Study leader's telephone:

+86 131 1958 0041

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

522790239@qq.com

研究负责人电子邮件:

Study leader's E-mail:

jilitu_z@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广东省广州市越秀区大德路111号

研究负责人通讯地址:

广东省广州市越秀区大德路111号

Applicant address:

111 Dade Road Yuexiu District Guangzhou City Guangdong Province

Study leader's address:

111 Dade Road Yuexiu District Guangzhou City Guangdong Province

申请注册联系人邮政编码:

Applicant postcode:

510120

研究负责人邮政编码:

Study leader's postcode:

510120

申请人所在单位:

广东省中医院

Applicant's institution:

Guangdong Provincial Hospital of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

BF2020-023

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

广东省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guangdong Provincial Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2023/4/4 0:00:00

伦理委员会联系人:

李晓彦

Contact Name of the ethic committee:

Li Xiaoyan

伦理委员会联系地址:

广东省广州市越秀区大德路111号

Contact Address of the ethic committee:

111 Dade Road Yuexiu District Guangzhou City Guangdong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 159 1312 3537

伦理委员会联系人邮箱:

Contact email of the ethic committee:

Z0572@163.com

研究实施负责(组长)单位:

广东省中医院

Primary sponsor:

Guangdong Provincial Hospital of Chinese Medicine

研究实施负责(组长)单位地址:

广东省广州市越秀区大德路111号

Primary sponsor's address:

111 Dade Road Yuexiu District Guangzhou City Guangdong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省中医院

具体地址:

广州市越秀区大德路111号

Institution
hospital:

Guangdong Provincial Hospital of Chinese Medicine

Address:

111 Dade Road, Yuexiu District, Guangzhou City

经费或物资来源:

广东省中医院院内专项2万元

Source(s) of funding:

Guangdong Provincial Hospital of Traditional Chinese Medicines in-hospital special project of RMB 20000

研究疾病:

外感发热

研究疾病代码:

Target disease:

patients with exogenous fever

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

1.评价中医握药疗法对外感发热患者的退热效果,为握药疗法提供临床研究证据支持。 2.制定出安全、有效的握药疗法退热的操作流程。 3.形成中医握药疗法退热的规范化护理方案。

Objectives of Study:

1. Evaluate the antipyretic effect of TCM medicine-holding therapy on patients with exogenous fever and provide clinical research evidence support for medicine-holding therapy. 2. Develop a safe and effective operating procedure for holding medicine to reduce fever. 3. Form a standardized nursing plan for antipyretic treatment using traditional Chinese medicine.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

①在广东省中医院各院区发热门诊以发热为主诉的就诊患者; ②均有外感诱因; ③年龄在>14 岁,性别不限; ④发病在 72小时以内,就诊时体温(耳温)≥38.0℃,未经治疗或自服药物无效者; ⑤自愿参加本试验,且签署知情同意书者;

Inclusion criteria

①Patients with fever as the main complaint in the fever clinics of the Guangdong Provincial Hospital of Traditional Chinese Medicine; ②All have external triggers; ③Age >18 years old gender is not limited; ④The onset of illness is within 48 hours and the body temperature (ear temperature) at the time of treatment ≥38.5℃ without treatment or self-administered drugs are ineffective; ⑤Those who voluntarily participate in this trial and sign the informed consent form;

排除标准:

①合并心、肺、肾、造血系统和内分泌系统等严重原发性疾病; ②细菌性感染; ③患者依从性差,不能配合握药者; ④掌心局部皮肤破溃或上肢残疾者;对本研究使用药物过敏者; ⑤妊娠或哺乳期妇女;

Exclusion criteria:

①Combined with serious primary diseases such as heart lung kidney hematopoietic system and endocrine system; ②Bacterial infection: purulent tonsillitis pneumonia and other inflammatory diseases; ③Patients with poor compliance and unable to cooperate with taking medicine; ④Part of the palm Those with skin ulcers or upper limb disabilities; those allergic to the drugs used in this study; ⑤ Pregnant or lactating women;

研究实施时间:

Study execute time:

From 2022-10-01

To      2025-09-30

征募观察对象时间:

Recruiting time:

From 2023-12-01

To      2024-07-01

干预措施:

Interventions:

组别:

对照组

样本量:

72

Group:

control group

Sample size:

干预措施:

采取常规退热治疗,辨证服用院内协方,必要时予物理降温,护理上嘱患者做好休息、多喝温热饮、做好饮食指导、密切观察体温变化、做好患者的心理护理。

干预措施代码:

2

Intervention:

Routine antipyretic treatment is adopted, hospital prescriptions are taken according to syndrome differentiation, and physical cooling is performed when necessary. The patient is instructed to rest well, drink more warm drinks, provide dietary guidance, closely observe changes in body temperature, and provide psychological care for the patient.

Intervention code:

组别:

干预组

样本量:

72

Group:

intervention group

Sample size:

干预措施:

在对照组的基础上增加中医握药疗法,成分有柴胡、青蒿各5g,荆芥、薄荷加减,研为细末,用姜汁和蜂蜜调成饼状,敷于两手心劳宫穴,常规握药30min,1次为1个疗程,共贴敷1个疗程。

干预措施代码:

1

Intervention:

On the basis of the control group, TCM medicine-holding therapy was added. The ingredients include 5g each of Bupleurum and Artemisia annua, plus or minus Schizonepeta and Mint. Grind into fine powder, mix it into a cake with ginger juice and honey, and apply it on both hands. Acupuncture points, hold the medicine for 30 minutes as usual, one time is one course of treatment, and a total of one course of treatment is applied.

Intervention code:

样本总量 Total sample size : 144

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省中医院

单位级别:

三甲

Institution/hospital:

Guangdong Provincial Hospital of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

口服布洛芬次数

指标类型:

次要指标

Outcome:

Oral ibuprofen times

Type:

Secondary indicator

测量时间点:

纳入研究后至72小时

测量方法:

计数

Measure time point of outcome:

Until 72 hours after study inclusion

Measure method:

count

指标中文名:

起效时间

指标类型:

次要指标

Outcome:

Onset of effect

Type:

Secondary indicator

测量时间点:

从服药开始到体温下降0.5℃所需时间

测量方法:

水银体温计测量腋温

Measure time point of outcome:

The time required from the start of taking the medicine until the body temperature drops by 0.5°C

Measure method:

Mercury thermometer measures armpit temperature

指标中文名:

痊愈时间

指标类型:

次要指标

Outcome:

recovery time

Type:

Secondary indicator

测量时间点:

自开始治疗到症状恢复至正常所需的时间,且并无起伏变化

测量方法:

水银体温计测量腋温

Measure time point of outcome:

The time required from the start of treatment until symptoms return to normal, without ups and downs

Measure method:

Mercury thermometer measures armpit temperature

指标中文名:

体温

指标类型:

主要指标

Outcome:

body temperature

Type:

Primary indicator

测量时间点:

干预前、干预后0.5h、1h、2h、6h、12h、24h、48h、72h

测量方法:

水银体温计测量腋温

Measure time point of outcome:

干预前、干预后0.5h、1h、2h、6h、12h、24h、48h、72h

Measure method:

Mercury thermometer measures armpit temperature

指标中文名:

疾病疗效评价

指标类型:

次要指标

Outcome:

Disease efficacy evaluation

Type:

Secondary indicator

测量时间点:

干预后72小时

测量方法:

根据体温和症状

Measure time point of outcome:

72 hours after intervention

Measure method:

Based on body temperature and symptoms

指标中文名:

解热时间

指标类型:

次要指标

Outcome:

antipyretic time

Type:

Secondary indicator

测量时间点:

自开始治疗到体温下降至 37℃ 所需时间

测量方法:

水银体温计测量腋温

Measure time point of outcome:

The time required from the start of treatment until the body temperature drops to 37°C

Measure method:

Mercury thermometer measures armpit temperature

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

结束

Completed

年龄范围:

最小 14
Min age years
最大 85
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

通过随机数字表法按 1:1 比例将研究对象分为治疗组和对照组。具体的随机分配方法:通过 SPSS24.0 软件运行随机数字生成器得出随机数字,并制成随机分配卡片,加不透光的信封密封保存,信封序号与卡片序号相同,并按编号顺序将信封依次排好。按照入组先后次序另纳入研究患者拆开信封,按信封内卡片上的规定进行分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

allocation cards seal them in an opaque envelope and store them in a sealed envelope. The envelope serial number is the same as the card serial number and the envelopes are placed in the order of numbering. Arrange them in order. According to the order of enrollment additional patients will be included in the study. Open the envelopes and group them according to the regulations on the card inside the envelope.

盲法:

本研究采用单盲法,即由一名不清楚患者分组的研究者对本研究的受试者进行疗效评价。

Blinding:

This study adopted a single-blind method, that is, a researcher who did not know the patient grouping evaluated the efficacy of the subjects in this study.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

http://www.medresman.org.cn/uc/index.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采用病例记录表进行数据的采集。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

A case record form was used to collect data.

数据管理委员会:

Data Managemen Committee:

No

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above